Prothena Corporation

Prothena Corporation ROCE

The Return on Capital Employed (ROCE) of Prothena Corporation (PRTA) as of Oct 5, 2026 is -65.80 %. In the previous year, Return on Capital Employed (ROCE) was -31.74 % — a change of 107.30% (lower).

ROCE

-65.80 %

YoY

107.30%

Last updated:

In 2026, Prothena Corporation's return on capital employed (ROCE) was -65.80 %, a 107.30% increase from the -31.74 % ROCE in the previous year.

The Prothena Corporation ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-49.18 USD
Jan 1, 2019
-31.40 USD
Jan 1, 2020
-61.27 USD
Jan 1, 2021
15.44 USD
Jan 1, 2022
-21.15 USD
Jan 1, 2023
-34.03 USD
Jan 1, 2024
-31.74 USD
Jan 1, 2025
-65.80 USD
The Prothena Corporation ROCE history
YEARROCEYoY
-65.80 %+107.30%
-31.74 %-6.72%
-34.03 %+60.91%
-21.15 %-236.94%
15.44 %-125.21%
-61.27 %+95.12%
-31.40 %-36.15%
-49.18 %+27.18%
-38.67 %-11.43%
-43.66 %+96.99%
-22.16 %+866.31%
-2.29 %—
Access this data via the Eulerpool API

Prothena Corporation Stock analysis

What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Prothena Corporation's Return on Capital Employed (ROCE)

Prothena Corporation's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Prothena Corporation's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Prothena Corporation's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Prothena Corporation’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Prothena Corporation stock

Return on Capital Employed (ROCE) of Prothena Corporation is -65.80 % in 2026.

Return on Capital Employed (ROCE) of Prothena Corporation changed from -31.74 % to -65.80 %, representing a 107.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Prothena Corporation with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

Profitability — Prothena Corporation

All Key Metrics — Prothena Corporation